Summit Therapeutics Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $705.0K | $1.8M | $860.0K | $743.0K |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $59.5M | $52.0M | $85.4M | $53.3M | $39.8M |
| SG&A Expense | $60.2M | $29.3M | $26.7M | $23.6M | $19.2M | $11.3M |
| Operating Income | $-226.0M | $-609.7M | $-72.1M | $-86.2M | $-53.2M | $-27.5M |
| Operating Margin | — | — | -10,225.4% | -4,764.3% | -6,185.2% | -3,697.6% |
| Interest Expense | — | $16.5M | $4.4M | $242.0K | $255.0K | $291.0K |
| Pretax Income | $-221.3M | $-614.9M | $-78.8M | $-88.6M | $-52.9M | $-29.1M |
| Income Tax Expense | $0 | $0 | — | $0 | $-213.0K | $36.0K |
| Net Income | $-221.3M | $-614.9M | $-78.8M | $-88.6M | $-52.7M | $-29.1M |
| Net Margin | — | — | -11,174.8% | -4,897.8% | -6,127.6% | -3,920.2% |
| EPS (Basic) | $-0.31 | $-0.99 | $-0.14 | $-0.22 | $-0.25 | $-0.15 |
| EPS (Diluted) | $-0.31 | $-0.99 | $-0.14 | $-0.22 | $-0.25 | $-0.15 |
| Shares Outstanding (Basic) | 718.5M | 619.6M | 580.0M | 395.1M | 208.6M | 197.0M |
| Shares Outstanding (Diluted) | 718.5M | 619.6M | 580.0M | 395.1M | 208.6M | 197.0M |
| Dividends Per Share | — | — | — | — | — | — |